Skip to content

Study · Non-randomized trial · n = 13 · 2013

6 results

Teriparatide treatment in adult patients with osteogenesis imperfecta type I.

Gatti D, Rossini M, Viapiana O, Povino MR, Liuzza S, Fracassi E, Idolazzi L, Adami S

Calcified tissue international2 Aug 2013Cited by 65 (Europe PMC)

PMID23907723 (opens in a new tab)DOI10.1007/s00223-013-9770-2 (opens in a new tab)PepBankPUB-23907723
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with type I osteogenesis imperfecta, teriparatide increased lumbar spine BMD from baseline.

    In plain wordsIn women with type I osteogenesis imperfecta, teriparatide increased lumbar bone density compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Measurements

    Lumbar spine BMD increase
    ≤ 3.5%
    over 18 months

    Source sentences

    Summary
    Bone mineral density (BMD) increased significantly over 18 months up to 3.5 % at the lumbar spine (p = 0.001), while no significant changes were noted in hip BMD.
    1 context sentence
    Summary · context
    Thirteen postmenopausal women with type I OI who had been on treatment with neridronate for at least 2 years and who incurred new vertebral fracture during treatment were treated with TPD for 18 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with type I osteogenesis imperfecta, hip BMD did not change significantly during teriparatide treatment.

    In plain wordsIn women with type I osteogenesis imperfecta, hip bone density did not change significantly with teriparatide compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeHip BMD
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Bone mineral density (BMD) increased significantly over 18 months up to 3.5 % at the lumbar spine (p = 0.001), while no significant changes were noted in hip BMD.
    1 context sentence
    Summary · context
    Thirteen postmenopausal women with type I OI who had been on treatment with neridronate for at least 2 years and who incurred new vertebral fracture during treatment were treated with TPD for 18 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with type I osteogenesis imperfecta, bone formation markers increased during teriparatide treatment.

    In plain wordsIn women with type I osteogenesis imperfecta, bone formation markers increased with teriparatide compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone formation markers
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum markers of bone formation and of bone resorption increased significantly during the treatment.
    1 context sentence
    Summary · context
    Thirteen postmenopausal women with type I OI who had been on treatment with neridronate for at least 2 years and who incurred new vertebral fracture during treatment were treated with TPD for 18 months.
  4. 04HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with type I osteogenesis imperfecta, bone resorption markers increased during teriparatide treatment.

    In plain wordsIn women with type I osteogenesis imperfecta, bone resorption markers increased with teriparatide compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone resorption markers
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum markers of bone formation and of bone resorption increased significantly during the treatment.
    1 context sentence
    Summary · context
    Thirteen postmenopausal women with type I OI who had been on treatment with neridronate for at least 2 years and who incurred new vertebral fracture during treatment were treated with TPD for 18 months.
  5. 05HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with type I osteogenesis imperfecta, sclerostin increased nonsignificantly during teriparatide treatment.

    In plain wordsIn women with type I osteogenesis imperfecta, sclerostin did not change significantly with teriparatide compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeSerum sclerostin
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    A nonsignificant increase was seen in serum sclerostin levels, while serum DKK1 rose gradually and significantly during TPD treatment.
    1 context sentence
    Summary · context
    Thirteen postmenopausal women with type I OI who had been on treatment with neridronate for at least 2 years and who incurred new vertebral fracture during treatment were treated with TPD for 18 months.
  6. 06HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with type I osteogenesis imperfecta, DKK1 increased gradually and significantly during teriparatide treatment.

    In plain wordsIn women with type I osteogenesis imperfecta, DKK1 increased with teriparatide compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum DKK1
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    A nonsignificant increase was seen in serum sclerostin levels, while serum DKK1 rose gradually and significantly during TPD treatment.
    1 context sentence
    Summary · context
    Thirteen postmenopausal women with type I OI who had been on treatment with neridronate for at least 2 years and who incurred new vertebral fracture during treatment were treated with TPD for 18 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.